Third Culture Capital

Investment decisions are led by Julien Pham, the firm's Founder and Managing Partner. Pham is a practicing nephrologist at Brigham and Women's Hospital in Boston, which gives him direct clinical-operational context when evaluating health-tech startups. The firm has not publicly disclosed additional investment committee members or junior partners.

The firm's deal flow is rooted in Pham's dual identity as a clinician and investor. Sourcing channels include academic medical center networks, clinical professional societies, health-tech founder communities, and referrals from other physician-investors. This model gives early access to clinician-founders who are solving workflow problems that are invisible to non-clinical investors.

The firm targets pre-seed and seed-stage companies, with initial checks generally ranging from $250,000 to $1 million. It reserves capital for follow-on investments through Series A rounds. Third Culture Capital typically leads or co-leads rounds alongside other early-stage health-tech investors.

The firm's primary focus is US innovation hubs — Boston, San Francisco, and New York — where the density of academic medical centers and health-tech founders is highest. Pham has evaluated deals in Toronto and London, but no cross-border portfolio companies have been confirmed as core positions.

The structural differentiator is Pham's ongoing clinical practice. Because he still treats patients at a major teaching hospital, the firm identifies investment opportunities through firsthand experience with clinical workflow failures, reimbursement friction, and regulatory gaps that generalist VCs only hear about secondhand. This physician-operator model is rare among institutional venture firms.